Macro
The Jobs Report That Flipped the Fed Script: What 172,000 Means for Markets
A 172,000 jobs report in May 2026 shocked markets and reversed expectations for Federal Reserve rate cuts. Here's what the data means for investors.
Macro
Tech
The Parabolic 7 Cracks: What the Chip Sector's Worst Day in Six Years Is Really Telling Investors
The semiconductor sector's worst day in six years reveals deeper concerns about valuation extremes and supply dynamics in the AI chip trade.
News
Greg Abel Has Launched: What Berkshire's $6.8 Billion Housing Bet Tells Us About the Post-Buffett Era
Greg Abel's first major acquisition as Berkshire CEO signals a more active approach to capital deployment and integration, marking the official beginning of the post-Buffett era.
Tech
Alphabet's $80 Billion Bet: When Google Goes to the Market to Win the AI Arms Race
Alphabet announced an $80 billion equity raise to fund AI infrastructure buildout, signaling its commitment to win the AI arms race. The deal includes a $10 billion Berkshire Hathaway investment and a $40 billion at-the-market offering program.
Tech
INNIO's $20 Billion IPO: How a GE Spinoff Became the Unlikely Power Broker of the AI Era
There is a number that tells the whole story of INNIO Holding's upcoming IPO better than any roadshow slide deck: 85. That is roughly how many times over the company's annual orders from data center customers have multiplied in just two years. In 2023, INNIO booked
Macro
Oil's Worst Month Since COVID: What the US-Iran Ceasefire Deal Means for Energy Markets
There is a number that energy traders have been watching with a mixture of relief and disbelief: 19. That is roughly how much Brent crude oil fell in percentage terms during May 2026 - its worst monthly performance since the COVID-19 pandemic sent demand off a cliff in 2020. The
Tech
The $1.75 Trillion Bet: What the SpaceX IPO Means for Markets, Investors, and the Future of Capital
There is a number that capital markets have never seen before: $75 billion. That is how much SpaceX is targeting to raise in its initial public offering, set to begin its roadshow on June 4 and price as early as June 11, with Nasdaq trading under the ticker SPCX expected
Macro
The Shekel Paradox: How Israel's Strongest Currency in 33 Years Is Threatening the Economy That Created It
There is a number that Israel's exporters have been watching with growing dread: 2.82. That is roughly how many shekels it takes to buy one US dollar today, a rate last seen in October 1993. For a country that has spent nearly three years on an effective
Macro
The Inflation Surprise Nobody Expected: What April PCE Data Means for the Fed's Next Move
April PCE came in at 2.1% headline and 2.5% core - a dramatic cooling that reshapes the Fed's June rate decision calculus and gives equity markets a fresh tailwind.
Macro
Goldman's 8,000 Call: What Wall Street's Boldest Upgrade Means for the Rest of 2026
Goldman Sachs raised its S&P 500 year-end target to 8,000, projecting 17% returns driven by AI-powered earnings growth. Here is what the upgrade means - and what could derail it.
Macro
Bond Vigilantes Are Back: What the 30-Year Treasury Yield Hitting 5.2% Means for Every Investor
There is a phrase that has not carried much weight in financial markets for the better part of two decades: bond vigilante. It refers to investors who punish governments for fiscal recklessness by selling their bonds, driving yields higher and borrowing costs up. For most of the post-2008 era,
Earnings
Lilly's $20 Billion Bet: Why the World's Hottest Drug Company Is Reinventing Itself as a Vaccine Giant
There is a phrase that gets used a lot in pharmaceutical strategy circles: "diversification beyond the blockbuster." The idea is simple. A drug company that depends on one or two mega-products for the bulk of its revenue is one patent cliff away from a crisis. Eli Lilly